Testing new drug combinations for advanced prostate cancer

Plain-English translation of NCT06353386 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This study is testing a new drug called for men with metastatic castration-resistant prostate cancer — a type of advanced prostate cancer that no longer responds to standard hormone treatments. You would receive either by itself or combined with one of several other cancer medications, depending on which group you are assigned to. The trial has two main phases: first, researchers will test the medication's safety and find the best dose; then, they will measure how well it works against the cancer.

Currently, men with advanced prostate cancer that stops responding to hormone therapy have limited treatment options, and existing treatments do not work for everyone. This trial is exploring whether this new medication can offer another effective option, either on its own or when paired with other proven cancer drugs.

Do you qualify?

You likely qualify if…

you have been diagnosed with adenocarcinoma of the prostate (the most common type of prostate cancer)
your prostate cancer has spread to other parts of your body and is no longer responding to hormone therapy
you have received one or two prior novel hormone treatments and your cancer has continued to progress
you have been on hormone-lowering therapy or had a surgical procedure for this purpose within 6 months
you have recovered from side effects of any previous cancer treatments

You likely don't qualify if…

you have a history of pituitary gland problems or adrenal insufficiency
you have poorly controlled diabetes or unstable heart disease
you have had a heart attack, stroke, or blood clots within the past 6 months
you have a history of a condition affecting bone marrow cells (MDS or AML)
you have had lung inflammation (pneumonitis) in the past that required steroid treatment

What participation looks like

You would take oral tablets (pills) twice daily, and depending on your assigned treatment group, you may also receive additional medications by mouth or intravenous infusions every three weeks. You would continue treatment until your cancer progresses or you decide to stop. Throughout the study, you would have regular visits for blood tests, imaging scans, and checkups to monitor how the medication is working and watch for side effects.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Testing new drug combinations for advanced prostate cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations